L-arginine is a basic amino acid with a guanidino sidechain. As an amino acid, metabolism of L-arginine to form L-ornithine, catalysed by arginase, forms the last step of the urea production cycle. L-Ornithine may be utilised as a precursor of polyamines (see Carboxylases and Decarboxylases) or recycled via L-argininosuccinic acid to L-arginine. L-Arginine may itself be decarboxylated to form agmatine, although the prominence of this pathway in human tissues is uncertain. L-Arginine may be used as a precursor for guanidoacetic acid formation in the creatine synthesis pathway under the influence of arginine:glycine amidinotransferase with L-ornithine as a byproduct. Nitric oxide synthase uses L-arginine to generate NO, with L-citrulline also as a byproduct.
L-Arginine in proteins may be subject to post-translational modification through methylation, catalysed by protein arginine methyltransferases. Subsequent proteolysis can liberate asymmetric NG,NG-dimethyl-L-arginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase activities. ADMA is hydrolysed by dimethylarginine dimethylhydrolase activities to generate L-citrulline and dimethylamine.
Arginase
Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is associated more with the kidney.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
||||||||||||
|
Nω-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform-selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are Nω-hydroxy-nor-L-arginine [13], S-(2-boronoethyl)-L-cysteine [4,9] and 2(S)-amino-6-boronohexanoic acid [2,4].
Arginine:glycine amidinotransferase
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
Arginine:glycine amidinotransferase Show »« Hide
|
Dimethylarginine dimethylaminohydrolases
Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
NG,NG-Dimethylarginine dimethylaminohydrolase 1 Show »« Hide
|
|||||||||||||||
|
NG,NG-Dimethylarginine dimethylaminohydrolase 2 Show »« Hide
|
Nitric oxide synthases
Nitric oxide synthases (NOS, E.C. 1.14.13.39) utilise L-arginine (not D-arginine) and molecular oxygen to generate NO and L-citrulline. The nomenclature suggested by NC-IUPHAR of NOS I, II and III [11] has not gained wide acceptance. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca2+/calmodulin and thus appears to be constitutively active. All the three isoforms are homodimers and require tetrahydrobiopterin, flavin adenine dinucleotide, flavin mononucleotide and NADPH for catalytic activity. L-NAME is an inhibitor of all three isoforms, with an IC50 value in the micromolar range.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
|||||||||||||||||||
|
|||||||||||||||||||
|
The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [10]. NADPH:O2 oxidoreductase catalyses the formation of superoxide anion/H2O2 in the absence of L-arginine and tetrahydrobiopterin.
Protein arginine N-methyltransferases
Protein arginine N-methyltransferases (PRMT, EC 2.1.1.-) encompass histone arginine N-methyltransferases (PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric or tetrameric enzymes which use S-adenosyl methionine as a methyl donor, generating S-adenosyl-L-homocysteine as a by-product. They generate both mono-methylated and di-methylated products; these may be symmetric (SDMA) or asymmetric (NG,NG-dimethyl-L-arginine) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
A related gene has been described, CARM1L (Coactivator associated arginine methyltransferase 1-like fragment, ENSG00000227835).
Bedford, MT; Clarke, SG. (2009) Protein arginine methylation in mammals: who, what, and why. Mol. Cell, 33 (1): 1-13. [PMID:19150423]
Heemskerk, S; Masereeuw, R; Russel, FG; Pickkers, P. (2009) Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol, 5 (11): 629-40. [PMID:19786992]
Huang, PL. (2009) eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol. Metab., 20 (6): 295-302. [PMID:19647446]
Krause, CD; Yang, ZH; Kim, YS; Lee, JH; Cook, JR; Pestka, S. (2007) Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol. Ther., 113 (1): 50-87. [PMID:17005254]
Kukreja, RC; Xi, L. (2007) eNOS phosphorylation: a pivotal molecular switch in vasodilation and cardioprotection?. J. Mol. Cell. Cardiol., 42 (2): 280-2. [PMID:17174975]
Leiper, J; Nandi, M. (2011) The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov, 10 (4): 277-91. [PMID:21455237]
Lundberg, JO; Weitzberg, E. (2010) NO-synthase independent NO generation in mammals. Biochem. Biophys. Res. Commun., 396 (1): 39-45. [PMID:20494108]
Maarsingh, H; Pera, T; Meurs, H. (2008) Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch. Pharmacol., 378 (2): 171-84. [PMID:18437360]
Maarsingh, H; Zaagsma, J; Meurs, H. (2009) Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br. J. Pharmacol., 158 (3): 652-64. [PMID:19703164]
Melikian, N; Seddon, MD; Casadei, B; Chowienczyk, PJ; Shah, AM. (2009) Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc. Med., 19 (8): 256-62. [PMID:20447567]
Moncada, S; Higgs, A; Furchgott, R. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol. Rev., 49 (2): 137-42. [PMID:9228663]
Morris, SM. (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol., 157 (6): 922-30. [PMID:19508396]
Mount, PF; Kemp, BE; Power, DA. (2007) Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol., 42 (2): 271-9. [PMID:16839566]
Munder, M. (2009) Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol., 158 (3): 638-51. [PMID:19764983]
Palm, F; Onozato, ML; Luo, Z; Wilcox, CS. (2007) Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol., 293 (6): H3227-45. [PMID:17933965]
Teyssier, C; Le Romancer, M; Sentis, S; Jalaguier, S; Corbo, L; Cavaillès, V. (2010) Protein arginine methylation in estrogen signaling and estrogen-related cancers. Trends Endocrinol. Metab., 21 (3): 181-9. [PMID:20005732]
Toda, N; Ayajiki, K; Okamura, T. (2009) Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol. Rev., 61 (1): 62-97. [PMID:19293146]
Tousoulis, D; Böger, RH; Antoniades, C; Siasos, G; Stefanadi, E; Stefanadis, C. (2007) Mechanisms of disease: L-arginine in coronary atherosclerosis--a clinical perspective. Nat Clin Pract Cardiovasc Med, 4 (5): 274-83. [PMID:17457351]
Tsutsui, M; Shimokawa, H; Otsuji, Y; Yanagihara, N. (2010) Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol. Ther., 128 (3): 499-508. [PMID:20826180]
1. Babbedge, RC; Bland-Ward, PA; Hart, SL; Moore, PK. (1993) Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br. J. Pharmacol., 110 (1): 225-8. [PMID:7693279]
2. Baggio, R; Emig, FA; Christianson, DW; Ash, DE; Chakder, S; Rattan, S. (1999) Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor. J. Pharmacol. Exp. Ther., 290 (3): 1409-16. [PMID:10454520]
3. Bland-Ward, PA; Moore, PK. (1995) 7-Nitro indazole derivatives are potent inhibitors of brain, endothelium and inducible isoforms of nitric oxide synthase. Life Sci., 57 (11): PL131-5. [PMID:7544863]
4. Colleluori, DM; Ash, DE. (2001) Classical and slow-binding inhibitors of human type II arginase. Biochemistry, 40 (31): 9356-62. [PMID:11478904]
5. Corbett, JA; McDaniel, ML. (1992) Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM. Diabetes, 41 (8): 897-903. [PMID:1378415]
6. Faraci, WS; Nagel, AA; Verdries, KA; Vincent, LA; Xu, H; Nichols, LE; Labasi, JM; Salter, ED; Pettipher, ER. (1996) 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br. J. Pharmacol., 119 (6): 1101-8. [PMID:8937711]
7. Garvey, EP; Oplinger, JA; Furfine, ES; Kiff, RJ; Laszlo, F; Whittle, BJ; Knowles, RG. (1997) 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J. Biol. Chem., 272 (8): 4959-63. [PMID:9030556]
8. Garvey, EP; Oplinger, JA; Tanoury, GJ; Sherman, PA; Fowler, M; Marshall, S; Harmon, MF; Paith, JE; Furfine, ES. (1994) Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J. Biol. Chem., 269 (43): 26669-76. [PMID:7523409]
9. Kim, NN; Cox, JD; Baggio, RF; Emig, FA; Mistry, SK; Harper, SL; Speicher, DW; Morris, SM; Ash, DE; Traish, A; et al.. (2001) Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry, 40 (9): 2678-88. [PMID:11258879]
10. Mayer, B; Hemmens, B. (1997) Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci., 22 (12): 477-81. [PMID:9433128]
11. Moncada, S; Higgs, A; Furchgott, R. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol. Rev., 49 (2): 137-42. [PMID:9228663]
12. Moore, WM; Webber, RK; Jerome, GM; Tjoeng, FS; Misko, TP; Currie, MG. (1994) L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J. Med. Chem., 37 (23): 3886-8. [PMID:7525961]
13. Tenu, JP; Lepoivre, M; Moali, C; Brollo, M; Mansuy, D; Boucher, JL. (1999) Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide, 3 (6): 427-38. [PMID:10637120]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |

